We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Statistical Model Helps Track T Cell Behavior During Cancer Immunotherapy

By LabMedica International staff writers
Posted on 20 Nov 2026

T cells play a central role in cancer immunotherapy, but their behavior can vary considerably, contributing to inconsistent treatment responses. While some T cells activate effectively, others become inactive or lose their ability to respond. Although T cell receptor clonality can indicate an anticancer immune response, cells with seemingly appropriate receptors may still fail to function. To better understand these differences, researchers have developed a computational method to measure and predict T cell behavior during immunotherapy.

Researchers at Memorial Sloan Kettering Cancer Center (MSK; New York, NY, USA) developed TCRi (T cell receptor information), a statistical model designed to monitor T cell responses to immunotherapies, including therapeutic cancer vaccines. The approach links the genetic identity of individual T cell receptors with the biological states of their corresponding cells, allowing researchers to investigate how receptor sequences influence T cell behavior and how these relationships change during immunotherapy.


Image Credit: iStock
Image Credit: iStock

TCRi combines information theory with single-cell analysis to examine two key characteristics of individual T cells. The first is the genetic sequence of the T cell receptor, which determines what the cell can recognize. The second is its gene expression profile, which reflects its functional state, such as active, exhausted, or naive. By analyzing these characteristics together, the model provides insights into the relationship between T cell identity and function.

Researchers applied the model to data from more than 167,000 T cells collected from cancer patients treated with immune checkpoint inhibitors. They found that T cells from nonresponders exhibited a stronger association between receptor clonotype and functional phenotype, a pattern already present before treatment that often became more pronounced after therapy began. In contrast, responders showed a weaker association before treatment, suggesting greater flexibility in T cell states that may enable more effective immune responses following immunotherapy.

The findings were published in Nature Genetics on November 5, 2026. The work involved MSK and the Olayan Center for Cancer Vaccines at MSK. The article also notes that TCRi has been used at MSK to monitor patient responses to vaccines, including an investigational personalized pancreatic cancer vaccine.

“This approach produces a standardized measurement that lets us compare results across different studies and clinical trials,” said Benjamin Greenbaum, Ph.D., computational biologist and co-director of neoantigen discovery at the Olayan Center for Cancer Vaccines at MSK. “We have a way to learn from this data what a meaningful T cell response to an immunotherapy looks like—or doesn't.”

“This tool offers a way to get a much clearer picture of what is biologically meaningful in T cell behavior,” said Greenbaum

Related Links
Memorial Sloan Kettering Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Automatic Hematology Analyzer
CF9600

Latest BioResearch News

Blood NAD Levels May Offer Clues to Cardiovascular Health
20 Nov 2026  |   BioResearch

Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
20 Nov 2026  |   BioResearch

Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
20 Nov 2026  |   BioResearch